In this episode, Professor Nicholas Lintzeris joins us to discuss where LAIB fits in contemporary opioid dependence treatment, how it compares with methadone and sublingual buprenorphine, and which patients are most likely to benefit. We also explore practical aspects of initiation, dosing, administration, management of adverse effects, and common misconceptions surrounding depot buprenorphine therapy.
Sublocade, will be removed from Australian markets at the end of 2026 . Made by US-based pharmaceutical company Indivior, the medication is one of two long-acting, slow-release buprenorphine injections on the Pharmaceutical Benefits Scheme (PBS) for opioid dependence treatment. Buvidal, remains available on the PBS.
Podden och tillhörande omslagsbild på den här sidan tillhör
Purple Pen Podcast. Innehållet i podden är skapat av Purple Pen Podcast och inte av,
eller tillsammans med, Poddtoppen.
